El tamaño del mercado global de servicios de organización de investigación por contrato (CROS) se valoró en USD 51,37 mil millones en 2020 y se proyecta que alcance los USD 92,32 mil millones para 2029, con una CAGR del 6,73% de 2022 a 2029.
El valor de los servicios de CRO producidos por organizaciones (organizaciones, propietarios únicos y sociedades) que externalizan servicios de investigación como administración de datos de ensayos clínicos , construcción y diseño de bases de datos, ingreso de datos y validación, codificación de enfermedades y atención médica, gestión de proyectos, informes de calidad y métricas, resúmenes de eficacia y seguridad, y planes e informes de análisis estadístico es lo que compone el mercado de producción de CRO. El valor de los servicios de CRO creados o generados por proveedores de servicios de CRO activos en un territorio determinado se incluye en el mercado de producción para esa geografía. Para reducir los costos de I+D y acelerar el tiempo que tarda un producto en llegar al mercado, las corporaciones farmacéuticas optan por subcontratar las fases preclínicas y de desarrollo de medicamentos a CRO. También se prevé que aumente la demanda de CRO por parte de proveedores farmacéuticos y biofarmacéuticos que deseen externalizar su I+D debido a la alta tasa de fracaso de los estudios clínicos.
Con cientos de pequeñas y medianas empresas y obstáculos mínimos para entrar en el sector, el sector de las CRO está extremadamente fragmentado. Pero sólo hay unas pocas CRO internacionales de gran tamaño que ofrecen un amplio abanico de conocimientos terapéuticos y de desarrollo, junto con una escala, capacidades, infraestructura de sistemas de TI y capacidad de análisis de datos importantes. En los últimos años se ha producido cierta consolidación en el mercado de las CRO, por lo que sólo quedan unas pocas CRO más grandes con la infraestructura global, la experiencia terapéutica y de desarrollo necesarias para respaldar y completar el riguroso programa de desarrollo de fármacos de las empresas biofarmacéuticas y de dispositivos médicos. Sin embargo, los paquetes de servicios que ofrecen las principales CRO a lo largo del ciclo de vida del desarrollo de fármacos son cada vez menos distintivos.
Over the projected period, the rising prevalence of chronic illnesses is anticipated to fuel market expansion for contract research organizations. A sedentary lifestyle, poor dietary habits, cigarette use, and smoking are a few of the major causes of the rising burden of chronic illnesses. Additionally, one of the main value drivers for research-based pharmaceutical and biotechnology firms is their focus on creating innovative medicines to address unmet medical needs. The pharmaceutical industry creates a number of cutting-edge medications with important clinical advantages, companion diagnostics. One of the key factors driving the amount of pharmaceutical research & development activities and, therefore, the market demand, is the escalating number of investments by both public and private organizations.
However, the market for CRO services is experiencing a significant slowdown due to a scarcity of skilled scientists and issues with allocating personnel expertise for certain projects. Additionally, the requirement for CRO service standardization in some nations is anticipated to slow the market's expansion overall. Furthermore, it is anticipated that the CROs' high operational expenses would have a detrimental effect on market growth. In the upcoming years, it is anticipated that factors including strict regulatory regulations, data privacy issues, and security concerns would further restrain the development rate of the worldwide CRO services market.
Established pharmaceutical businesses are gravitating towards smaller business models with a strong dependency on outside parties, such as CROs. There are now more businesses engaged in research and medication development as a result of the biotech sector's, clinical trials tremendous expansion over the past ten years. For those working in the contract research organization (CRO) services sector, the exponential growth in the number of existing and future drug development businesses and research projects generated a tremendous window of opportunity. Over the past ten years, outsourcing of significant or complicated parts of the drug development process has become essential for the efficient and economical creation of new medications.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD Billion) |
| Segmentation | By Service Type, By Application, By End Use, By Region. |
| By Service Type |
|
| By Application |
|
| By End Use |
|
| By Region |
|
The contract research organization services (CROS) market is expected to reach USD 62.46 billion by the end of 2023.
Increasing use of virtual and decentralized trials is a key trend gaining popularity.
The global contract research organization services (CROS) market size was valued at USD 51.37 billion in 2020, and projected to reach USD 92.32 billion by 2029, with a CAGR of 6.73% from 2022 to 2029.
The global market is fragmented in nature with the presence of various key players such as Laboratory Corporation of America Holdings, IQVIA Inc., Syneos Health, Inc., Parexel International Corporation, Charles River Laboratories, Inc., Icon plc, WuXi AppTec Group, Medpace, Clinical Trial Service B.V., CTI Clinical Trial and Consulting Inc., Geneticist Inc., Linical Co. Ltd., Novotech Health Holdings, Pharmaron Beijing Co. Ltd.
The North America dominated the global industry in 2021 and accounted for the maximum share of more than 63% of the overall revenue.
Due to the increased prevalence of numerous chronic diseases and the growing need for more potent and sophisticated medications, the clinical research services segment accounted for the greatest revenue share in 2021. To assess the efficacy of novel medications that aim to enhance patients' health, clinical research is required. Additionally, clinical research is crucial for developing medications to treat chronic and degenerative illnesses, fight disease, and improve global health. As pharma businesses outsource these activities to CROs to minimize additional operating expenses and concentrate on other tasks, the laboratory services market is anticipated to see a considerably rapid pace of revenue growth throughout the projected period.
Due to the high prevalence of cancer worldwide and continuing pipeline efforts to create potent medications for the condition, the oncology section accounted for the greatest revenue share in 2021. high need for the creation of innovative medications and treatments, which in turn is driving up the demand for research methods to be outsourced. The cost and complexity of clinical trials have also risen as a result of rigorous regulatory requirements and severe penalties for noncompliance. The therapeutic area of oncology, which is the most active and quickly growing in the CRO, is now receiving the greatest amount of focus in clinical development.
Due to rising expenditures in research and development by biopharmaceutical businesses in recent years, the biopharmaceutical industry is anticipated to account for a considerably big revenue share throughout the projection period. To avoid paying for internal research infrastructure, some businesses are outsourcing their research and development to CROs. Increased investment from private equity and venture capital firms is leading to a rise in the number of new biopharmaceutical companies. These companies usually lack the internal resources necessary to conduct research and development, therefore they outsource these tasks to CROs, which is anticipated to fuel this market segment's revenue growth.
[caption id="attachment_28905" align="aligncenter" width="1920"]
The global market is fragmented in nature with the presence of various key players such as Laboratory Corporation of America Holdings, IQVIA Inc., Syneos Health, Inc., Parexel International Corporation, Charles River Laboratories, Inc., Icon plc, WuXi AppTec Group, Medpace, Clinical Trial Service B.V., CTI Clinical Trial and Consulting Inc., Geneticist Inc., Linical Co. Ltd., Novotech Health Holdings, Pharmaron Beijing Co. Ltd. along with medium and small-scale regional players operating in different parts of the world. Major companies in the market compete in terms of application development capability, product launches, and development of new technologies for product formulation.
May 3, 2023 - An agreement to establish a strategic partnership with Jefferson Health (Jefferson) was announced by the Labcorp corporation. When everything is said and done, the agreements between Jefferson and Labcorp will help to form academic partnerships for teaching and the creation of cutting-edge exams. May 1, 2023 - The introduction of Accugenix Next Generation Sequencing for Bacterial Identification and Fungal Identification was announced by Charles River Laboratories International, Inc. Millions of individual DNA fragments from a sample were concurrently sequenced by Accugenix NGS, which gives pharmaceutical and personal care firms important knowledge about microbial control. March 10, 2023 - A strategic alliance between LEO Pharma, a market leader in medical dermatology, and ICON plc has been announced. Through this alliance, LEO Pharma will be able to scale patient-centered and cost-effective clinical trial execution, furthering its overall goal of creating one of the most effective and efficient clinical portfolio execution organisations in the sector.Geographically, the contract research organization services (CROS) market is segmented into North America, South America, Europe, APAC and MEA.
During the forecast period, North America is anticipated to contribute 63% to the growth of the worldwide market. The R&D of medications in advanced clinical trials is still most frequently outsourced by pharmaceutical companies to North America. The region's cutting-edge healthcare system makes it possible to identify the patient population through early diagnosis of a variety of indications. Early-stage illness therapy will benefit from this. The regional contract research organization (CRO) market is expanding as a result of factors including having access to a sizable patient pool for a variety of diseases to perform late-stage clinical studies.
[caption id="attachment_28907" align="aligncenter" width="1920"]
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.